Shares of GlobeImmune Inc (OTCMKTS:GBIM) ended Monday session in red amid volatile trading. The shares closed down -0.030 points or -3.50% at $0.830 with 25,927 shares getting traded. Post opening the session at $0.86, the shares hit an intraday low of $0.73 and an intraday high of $0.86 and the price vacillated in this range throughout the day. The company has a market cap of $5.63 million and the numbers of outstanding shares have been calculated to be 5.75 million shares.
GlobeImmune Inc (GBIM) recently offered an update on the Company’s business and clinical programs and declared financial results for the first quarter 2016.
The Company continues to seek potential planned transactions. Cantor Fitzgerald & Co. has been retained by the Company to assist in reviewing ways to maximize stockholder value. There is not a defined timeline for the planned review process and the review may not result in any specific action or transaction.
The Company has three ongoing clinical trials being conducted by the Company’s corporate collaborators, Gilead Sciences, Inc. and Celgene Corporation. GS-US-330-1401, the GS-4774 Phase 2 clinical trial in patients with chronic HBV infection who are presently not receiving treatment, is fully enrolled and the 48-week results are projected to be available in the second half of 2016. The 24-week results for this trial did not show a statistical difference between control and treatment arms. The results from a GI-6207 Phase 2 trial in subjects with medullary thyroid cancer are projected to be available in the second half of 2016. A Phase 2 clinical trial designed to investigate the safety and efficacy of evaluating GI-6301 in combination with radiation therapy in patients with chordoma is still enrolling patients.
Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Monday session in red amid volatile trading. The shares closed down -0.10 points or -3.19% at $3.03 with 355,674 shares getting traded. Post opening the session at $3.21, the shares hit an intraday low of $2.91 and an intraday high of $3.21 and the price vacillated in this range throughout the day. The company has a market cap of $21.16 million and the numbers of outstanding shares have been calculated to be 3.27 million shares.
Skyline Medical Inc (SKLN) declares that it has agreed to grant GLG Pharma, LLC (“GLG”) exclusive rights to market and distribute the STREAMWAY® System in Poland and certain other countries in Central Europe. This builds upon a formerly declared arrangement granting GLG exclusive rights to market and distribute STREAMWAY in the U.K. and an initial agreement to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures.
GLG will be responsible for all sales and marketing activities, counting hiring and training the appropriate number of direct sales representatives to cover the 3,800 operating rooms in Poland. Marketing is expected to begin right away upon receipt of the CE Mark and will be managed from GLG’s facility in Gdansk, Poland.
The agreement will also include the Czech Republic, Latvia, Estonia and Lithuania, with sales activities expected to begin in those countries soon after the introduction in Poland. Skyline applied for CE Mark approval to market STREAMWAY in the European Union and certain other countries in July 2016, following receipt of ISO 13485:2003 certification.